Tagged with M

China Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the country over the past decades, its strengths as a diversified healthcare company offering not only pharmaceutical products but medical devices…

Hungary Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors to truly deliver on its innovation potential.   On the Up Globally, R&D spending has been on a sturdy upward…

Puerto Rico Jose Viera-Colon, Region Director Caribbean for Allergan, highlights the opportunities and obstacles related to leading the company’s commercial operations in Puerto Rico and countries like the Dominican Republic. He also gives insights in planned product launches in CNS and eyecare and explains Allergan’s approach to ensure product affordability for Puerto…

Artificial Intelligence IBM Watson Health’s Director for Global Life Sciences & Go-To Market Leader for Europe & Asia Pacific Christina Busmalis gives her insights into how AI and greater utilisation of real-world evidence is shaping the global biopharmaceutical industry, including the tangible results she has seen so far, and the lengthy path…

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

Europe Awareness is growing of the dangers of healthcare-associated infections (HAIs) in Europe, and conversations are beginning to taking place around how to leverage data to combat these infections and antimicrobial resistance (AMR). A panel of experts from diverse backgrounds at the European Health Forum Gastein put their heads together to…

4+7 China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.   Pharma companies in China are facing yet another intense race to the bottom on pricing. On the 24th of…

Puerto Rico David Fuster, plant manager of the Dorado factory of Chinese pharma outfit PuraCap, shares the company’s strategy behind the investment in Puerto Rico and how the PuraCap Caribe is leveraging technologies at the facility for new product development. He underlines the importance of Puerto Rico as a manufacturing location for…

UAE The mission of the Swiss Business Council (SBC) is to provide a forum for Swiss executives and those with Swiss business interested to identify, discuss and pursue common interests regarding their activities. Peter Harradine, president of SBC Dubai & Northern Emirates discusses FDI inflows into the UAE, the strategic significance…

Puerto Rico Iliette Frontera, VP Operations of Boston Scientific in Puerto Rico, shares the significance of the Dorado site within the group’s global supply chain, her four priorities to ensure sustainable growth, lessons learned from Hurricane Maria, and the importance of gender equality.   You have to be extremely agile and you…

Sweden Johan Folkunger, CEO of Philips Sweden, discusses the transformation from a conglomerate into a healthtech company focused on health and wellbeing, the unique partnership with the Karolinska University Hospital including the establishment of a global research hub in Sweden, and the effort to move healthcare away from the hospitals. Folkunger…